Collegium Pharmaceutical, Inc. Proceeds from Common Stock Issued
Collegium Pharmaceutical, Inc. (COLL) reported Proceeds from Common Stock Issued of -$30.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2021-02-25
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for the quarter ending 2017-12-31 was $24.91M, a 70.94% decline year-over-year.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for the quarter ending 2016-12-31 was $85.72M.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for the quarter ending 2016-09-30 was $445.00K.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for the quarter ending 2016-06-30 was $0.00.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for fiscal 2018 was -$30.00K, a 100.09% decline from fiscal 2017.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for fiscal 2017 was $34.34M, a 75.00% decline from fiscal 2016.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for fiscal 2016 was $137.34M, a 90.67% increase from fiscal 2015.
- Collegium Pharmaceutical, Inc. proceeds from issuance of common stock for fiscal 2015 was $72.03M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$30.00K 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $24.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $34.34M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $9.43M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $85.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $86.17M derived: sum of 2 quarters · filed 2019-02-27 | $86.17M derived: sum of 3 quarters · filed 2019-02-27 | $137.34M 10-K · filed 2019-02-27 |
| 2016-09-30 | $445.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $445.00K derived: sum of 2 quarters · filed 2017-11-08 | $51.62M 10-Q · filed 2017-11-08 | $51.62M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $51.17M 10-Q · filed 2017-08-09 | $51.17M derived: sum of 3 quarters · filed 2018-03-07 | |
| 2016-03-31 | $51.17M 10-Q · filed 2017-05-10 | $51.17M derived: sum of 2 quarters · filed 2018-03-07 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $72.03M 10-K · filed 2018-03-07 | ||
| 2015-09-30 | $72.03M 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |